This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Local Minneapolis Star And Tribune Reporter James Walsh Cracks The Need For SEC Disclosures From Device Manufacturers In The Myxo File Part III

CHICAGO, Jan. 31, 2013 /PRNewswire/ - The Myxo File Part I and part II reveals the truth surrounding the Clinical trials testing heart devices between 2003-2009. Soon after Mr. James Walsh published in the Minneapolis Star and Tribune, the full disclosure by St. Jude to investors, he reported:

(Photo: http://photos.prnewswire.com/prnh/20130131/TO530)

"The U.S. Food and Drug Administration has sent a warning letter to St. Jude Medical regarding manufacturing processes at a facility in Southern California, St. Jude and the FDA have confirmed and reported January 14, 2013".

The Myxo File Part III was recently written and published on Kindle Direct Publishing linking the importance of full disclosure by Medical Device Manufacturers and Medical Device Safety for Citizens across the world. Providential Meeting with the President of the United States is described in the Biographical story to make device safety a top issue for US hospitals across the United States.

Nalini M. Rajamannan, MD is the author of the Myxo File Part I, Part II, and Part III, which has published the original documents supporting this release on Amazon and Kindle Direct Publishing, Rajamannan is the CEO of Concie Valve LLC.

SOURCE ConcieValve LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs